## WHAT IS CLAIMED IS:

A compound of the formula:

$$Y_2^l \underbrace{ U }_{D_a} \underbrace{ D_b }_{D_b} \underbrace{ A^2_A ^{l} \overset{R^l}{N}_R^2}$$

wherein

1

2

4

5

6

7

8

17

18 19

20

21

23

24

 $R^1$  and  $R^2$  are each members independently selected from the group consisting of hydrogen,  $(C_1-C_8)$ alkyl,  $(C_1-C_8)$ heteroalkyl, aryl, heteroaryl, aryl $(C_1-C_8)$ heteroalkyl, heteroaryl $(C_1-C_8)$ heteroalkyl, with the proviso that at least one of  $R^1$  and  $R^2$  is selected from the group consisting of aryl, heteroaryl, aryl $(C_1-C_8)$ alkyl, aryl $(C_1-C_8)$ heteroalkyl, heteroaryl $(C_1-C_8)$ alkyl and heteroaryl $(C_1-C_8)$ heteroalkyl;

 $A^1 \ is \ a \ member selected \ from \ the \ group \ consisting \ of \ L\text{-}\alpha\text{-}amino \ acid}$  fragments, D-\$\alpha\$-amino acid fragments and fragments having the formula:

wherein

R<sup>3</sup> is selected from the group consisting of hydrogen and (C<sub>1</sub>-C<sub>4</sub>) alkyl;

R<sup>4</sup> and R<sup>5</sup> are each members independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, or can be individually combined with R<sup>3</sup> to form a 5-, 6-, 7- or 8-membered ring containing from one to three heteroatoms;

 $A^2$  is a member selected from the group consisting of L- $\alpha$ -amino acid fragments, D- $\alpha$ -amino acid fragments and fragments having the formula:

22 wherein

 $R^6$  is selected from the group consisting of hydrogen and (C<sub>1</sub>-C<sub>4</sub>)alkyl;  $R^7$  and  $R^8$  are each members independently selected from the group

. 25 consisting of hydrogen, (C1-C8)alkyl and (C1-C8)heteroalkyl, or can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to 26 27 three heteroatoms: X is a member selected from the group consisting of a bond, a (C<sub>1</sub>-C<sub>4</sub>) 28 29 saturated or unsaturated alkylene linking group and a (C<sub>1</sub>-C<sub>4</sub>) saturated or unsaturated 30 heteroalkylene linking group: D<sub>a</sub>, D<sub>b</sub> and D<sub>c</sub> are each independently selected from the group consisting of 31 32 =N- and  $=C(R^9)-$ 33 wherein each R9 is independently selected from the group consisting of hydrogen. 34 halogen, cyano, nitro, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, 35  $-NR^{10}R^{11}$ ,  $-C(O)OR^{10}$ ,  $-C(O)NR^{10}R^{11}$ ,  $-O-C(O)OR^{10}$ ,  $-NR^{11}$ ,  $-C(O)OR^{10}$ ,  $-NR^{10}$ - $SO_2R^{12}$ ,  $-SO_2R^{12}$ 36 37 38 39 40 41 NR10-C(O)R11, -SO2NR10R11, and -OC(O)NR10R11; wherein each R<sup>10</sup> and R<sup>11</sup> are each independently a member selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, or when attached to the same nitrogen atom can be combined with each other to form a 5-, 6-, 7- or 8-membered ring 42 containing from zero to three heteroatoms; and 43 each R<sup>12</sup> is independently a member selected from the group consisting of (C<sub>1</sub>-44 C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl and heteroaryl; 45 U and Z are each independently selected from the group consisting of a single bond, -CH2-, -CH(OH)-, -C(O)-, -CH2O-, -CH2CH2-, -CH2C(O)-, -O-, -S-, -S-CH2-, -N(C(O)-46 (C<sub>1</sub>-C<sub>9</sub>)alkyl)-, -N(R<sup>13</sup>)- and -N(R<sup>13</sup>)-CH<sub>2</sub>-; 47 48 wherein each R<sup>13</sup> is a member selected from the group consisting of hydrogen, (C<sub>1</sub>-49 50 C<sub>8</sub>)alkyl, aryl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; Y<sup>1</sup> and Y<sup>2</sup> are each independently selected from the group consisting of -51 CO2H and -CO2R14; and 52 R14 is a member selected from the group consisting of (C1-C9)alkyl, and (C1-53 Co)heteroalkyl, or, alternatively, when Y<sup>1</sup> and Y<sup>2</sup> are each -CO<sub>2</sub>R<sup>14</sup>, each R<sup>14</sup> and the oxygen 54 55 to which it is attached, join to form a 5-, 6-, 7- or 8-membered heterocyclic ring. 1 2. The compound of claim 1, wherein D<sub>a</sub>, D<sub>b</sub> and D<sub>c</sub> are each =CH-.

.

1

2

3

4

- 1 3. The compound of claim 1, wherein X is a (C2-C4) unsaturated alkylene 2 linking group.
- The compound of claim 1, wherein A<sup>1</sup> is selected from the group 1 4. 2 consisting of L-\alpha-amino acid fragments.
- The compound of claim 1, wherein A<sup>2</sup> is selected from the group 1 5. 2 consisting of L-α-amino acid fragments.
- The compound of claim 1, wherein A<sup>1</sup> and A<sup>2</sup> are each independently 1 6. selected from the group consisting of L-α-amino acid fragments. 2
  - The compound of claim 1, wherein A<sup>1</sup> and A<sup>2</sup> are each independently 7. selected from the group consisting of L-α-amino acid fragments; X is a (C2-C4) unsaturated alkylene linking group; and Da, Db and Dc are each =CH-.
  - The compound of claim 1, wherein U is selected from the group consisting of -CH2- and -CH(OH)-.
  - 9. The compound of claim 1, wherein Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-.
  - The compound of claim 1, wherein U is selected from the group 10. consisting of -CH2- and -CH(OH)-; and Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-.
  - The compound of claim 1, wherein A<sup>1</sup> and A<sup>2</sup> are each independently 11. selected from the group consisting of a natural or unnatural L-α-amino acid fragments: X is a (C2-C4) unsaturated alkylene linking group; D3, Db and Dc are each = CH-; U is selected from the group consisting of -CH<sub>2</sub>- and -CH(OH)-; and Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-.
- The compound of claim 11, wherein X is an unsaturated alkylene 1 12. 2 moiety selected from the group consisting of -C(CH<sub>3</sub>)=CH and -CH=C(CH<sub>3</sub>).
- The compound of claim 1, wherein R1 and R2 are each members 1 13 2 independently selected from the group consisting of (C1-C8)alkyl, aryl and aryl(C1-C8)alkyl.

1

2

1

2

- The compound of claim 11, wherein R1 and R2 are each members 14. independently selected from the group consisting of (C1-C8)alkyl, arvl and arvl(C1-C8)alkyl.
- The compound of claim 1, wherein R1 is an optionally substituted 1 15. 2 phenyl group.
  - The compound of claim 1, wherein R1 is an optionally substituted 16. phenyl group and R2 is an optionally substituted benzyl group.
- The compound of claim 11, wherein R1 is an optionally substituted 1 17. 2 phenyl group.
  - The compound of claim 11, wherein R1 is an optionally substituted 18. phenyl group and R2 is an optionally substituted benzyl group.
  - The compound of claim 1, wherein R1 is an optionally substituted (C1-19. C<sub>8</sub>)alkyl or (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl group and R<sup>2</sup> is an optionally substituted phenyl or benzyl group.
  - The compound of claim 1, wherein R1 is a phenyl group substituted 20. with up to two members selected from the group consisting of -NHCONH2, -C(NH)NH2, -CONH2. -CH2NHCO-(4-nitro-2-pyrazolyl). -CONHPh. -CH2NH2. -CH2NHCO-CH=CH-(3nitrophenyl), -CH<sub>2</sub>, -Cl, -Br, -I, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, -OH, -Ph, -OPh, -CON(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl).
- The compound of claim 11, wherein R1 is an optionally substituted 1 21. (C<sub>1</sub>-C<sub>8</sub>)alkyl or (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl group and R<sup>2</sup> is an optionally substituted phenyl or benzyl 2 3 group.
- The compound of claim 11, wherein R<sup>1</sup> is a phenyl group substituted 1 22. with up to two members selected from the group consisting of -NHCONH2, -C(NH)NH2, -2 3 CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3-4 nitrophenyl), -CH3, -Cl, -Br, -I, -CO2H, -CO2CH3, -OCH3, -OH, -Ph, -OPh, -CON(CH3)2, -C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl). 5
- The compound of claim 11, wherein Z is -O-: R1 is a member selected 1 23. from the group consisting of an optionally substituted phenyl group or an optionally 2

2 3

1

2 3

3 4

5

1

2 1

2

3

1

2

- substituted heteroaryl; and R<sup>2</sup> is a member selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl. (C1-C3)heteroalkyl, arvl(C1-C3)alkyl, arvl(C1-C3)heteroalkyl, heteroarvl(C1-C3)alkyl and heteroaryl(C1-C8)heteroalkyl.
- The compound of claim 4, wherein A<sup>1</sup> is an L-α-amino acid fragment 24. derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-proline,
- 25. The compound of claim 5, wherein A2 is an L-α-amino acid fragment derived from L-valine, L-leucine, L-methionine, L-lysine, L-isoluecine, L-threonine and Ltert-butylglycine.
- The compound of claim 11, wherein A<sup>1</sup> is an L-α-amino acid fragment 26. derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-proline; and A<sup>2</sup> is an L-αamino acid fragment derived from L-valine, L-leucine, L-methionine, L-lysine, L-isoluecine, L-threonine and L-tert-butylglycine.
- The compound of claim 26, wherein R<sup>1</sup> and R<sup>2</sup> are each members 27. independently selected from the group consisting of substituted or unsubstituted (C1-C2)alkyl. substituted or unsubstituted aryl and substituted or unsubstituted aryl(C1-C8)alkyl.
- The compound of claim 27, wherein A<sup>1</sup> is an L-α-amino acid fragment 28. derived from L-alanine or L-proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from Lvaline, L-leucine, L-isoluecine, or L-tert-butylglycine.
- The compound of claim 27, wherein A<sup>1</sup> is an L-α-amino acid fragment 29. derived from L-proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from L-tertbutylglycine.
  - 30. The compound of claim 1, having the formula:

wherein

9

10

11 12

13

14 1

W1 is a member selected from the group consisting of -H. -OR15 and

-NR15R16:

4 5

6

7

8

9 10

11

12 1

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group

consisting of hydrogen, halogen, -R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>: wherein R15, R16, R17 and R18 are each members independently selected from

the group consisting of hydrogen, arvl. (C<sub>1</sub>-C<sub>2</sub>)alkyl. (C<sub>1</sub>-C<sub>2</sub>)heteroalkyl. arvl(C<sub>1</sub>-C<sub>2</sub>)alkyl. arvl(C1-C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

## 31. The compound of claim 1, having the formula:

wherein

R<sup>2</sup> is a member selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl;

W1 is a member selected from the group consisting of -H, -OR15 and -NR15R16:

W<sup>2</sup> is a member selected from the group consisting of hydrogen, halogen,

-R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>:

wherein R15, R16, R17 and R18 are each members independently selected from the group consisting of hydrogen, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, arvl(C1-C8)heteroalkyl, alkylsulfonyl, arvlsulfonyl and arvlsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

## 32. The compound of claim 1, having the formula:

4

5

6

7

8

3 4

5

6

7

8 9

10

11 12

wherein

W1 is a member selected from the group consisting of -H. -OR15 and

-NR 15R 16 ·

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group consisting of hydrogen, halogen, -R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>;

wherein R15, R16, R17 and R18 are each members independently selected from the group consisting of hydrogen, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, arvl(C1-C8)heteroalkyl, alkylsulfonyl, arvlsulfonyl and arylsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

33. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:

$$\underbrace{Y^{1}}_{Y^{2}} \underbrace{U}_{Z} \underbrace{D^{1}_{c}}_{D_{c}} \underbrace{X}_{D_{c}} \underbrace{A^{2}_{A^{1}}}_{N} \underbrace{N^{1}_{R^{2}}}_{N^{2}}$$

wherein

R<sup>1</sup> and R<sup>2</sup> are each members independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, heteroaryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, and heteroaryl(C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, with the proviso that at least one of R<sup>1</sup> and R<sup>2</sup> is selected from the group consisting of aryl, heteroaryl, aryl(C1-C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl(C1-C8)alkyl and heteroaryl(C1-C<sub>8</sub>)heteroalkvl:

A1 is a member selected from the group consisting of L-α-amino acid fragments, D-α-amino acid fragments and fragments having the formula:

13 14 wherein 15 R³ is selected from the group consisting of hydrogen and (C₁-C₄) alkyl;
16 R⁴ and R⁵ are each members independently selected from the group
17 consisting of hydrogen, (C₁-C₃)alkyl and (C₁-C₃)heteroalkyl, or can be
18 individually combined with R³ to form a 5-, 6-, 7- or 8-membered ring containing from one to
19 three heteroatoms;
20 A² is a member selected from the group consisting of L-α-amino acid

 $A^*$  is a member selected from the group consisting of L- $\alpha$ -amino acid fragments, D- $\alpha$ -amino acid fragments and fragments having the formula:



wherein

  $R^6$  is selected from the group consisting of hydrogen and  $(C_1\text{-}C_4)alkyl;$   $R^7$  and  $R^8$  are each members independently selected from the group consisting of hydrogen,  $(C_1\text{-}C_8)alkyl$  and  $(C_1\text{-}C_8)heteroalkyl$ , or can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms:

X is a member selected from the group consisting of a bond, a  $(C_1-C_4)$  saturated or unsaturated alkylene linking group and a  $(C_1-C_4)$  saturated or unsaturated heteroalkylene linking group;

 $D_a, D_b \mbox{ and } D_c \mbox{ are each independently selected from the group consisting of}$  =N- and =C(R $^9$ )-

wherein

each  $R^0$  is independently selected from the group consisting of hydrogen, halogen, cyano, nitro,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ heteroalkyl,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ thioalkoxy, -  $NR^{10}R^{11}$ , - $(C)OOR^{10}$ , - $(C)ONR^{10}R^{11}$ , - $(C)OOR^{10}$ , - $(C)ONR^{10}R^{11}$ , - $(C)OOR^{10}$ , - $(C)OOR^{10}R^{11}$ , and - $(C)OOR^{10}R^{11}$ :

wherein

each  $R^{10}$  and  $R^{11}$  are each independently a member selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, or when attached to the same nitrogen atom can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms; and

each  $R^{12}$  is independently a member selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, arvl and heteroaryl;

2

1

2

46 47 48

U and Z are each independently selected from the group consisting of a single
bond, -CH <sub>2</sub> -, -CH(OH)-, -C(O)-, -CH <sub>2</sub> O-, -CH <sub>2</sub> CH <sub>2</sub> -, -CH <sub>2</sub> C(O)-, -O-, -S-, -S-CH <sub>2</sub> -,
$-N(C(O)-(C_1-C_9)alkyl)-, -N(R^{13})- and -N(R^{13})-CH_2-;$

wherein

R13 is a member selected from the group consisting of H. (C1-C0)alkyl, arvl and (C1-C0)heteroalkyl:

Y<sup>1</sup> and Y<sup>2</sup> are each independently selected from the group consisting of -CO2H and -CO2R14

wherein

- R<sup>14</sup> is a member selected from the group consisting of (C<sub>1</sub>-C<sub>9</sub>)alkyl, (C<sub>1</sub>-C<sub>0</sub>) heteroalkyl, or, alternatively, when Y<sup>1</sup> and Y<sup>2</sup> are each -CO<sub>2</sub>R<sup>14</sup>, each R<sup>14</sup> and the oxygen to which it is attached, join to form a 5-, 6-, 7-, or 8-membered heterocyclic ring.
- 34. The pharmaceutical composition of claim 33, wherein Da, Dh and Dc are each =CH-.
- The pharmaceutical composition of claim 33, wherein X is a (C2-C4) 35. unsaturated alkylene linking group.
- The pharmaceutical composition of claim 33, wherein A1 is selected 36. from the group consisting of L-α-amino acid fragments.
- The pharmaceutical composition of claim 33, wherein A2 is selected 37. from the group consisting of L-α-amino acid fragments.
- The pharmaceutical composition of claim 33, wherein A<sup>1</sup> and A<sup>2</sup> are 38. each independently selected from the group consisting of L-α-amino acid fragments.
- The pharmaceutical composition of claim 33, wherein A1 and A2 are 1 39. each independently selected from the group consisting of L-α-amino acid fragments; X is a 2 3 (C2-C4) unsaturated alkylene linking group; and D0, D5 and Dc are each =CH-.
- 1 40. The pharmaceutical composition of claim 33, wherein U is selected 2 from the group consisting of -CH2- and -CH(OH)-.
- 1 41. The pharmaceutical composition of claim 33, wherein Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-. 2

1

2

1

2

1

2

3

1

2

3

4 5

- 42. The pharmaceutical composition of claim 33, wherein U is selected from the group consisting of -CH<sub>2</sub>- and -CH(OH)-; and Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-.
  - The pharmaceutical composition of claim 33, wherein A<sup>1</sup> and A<sup>2</sup> are 43. each independently selected from the group consisting of a natural or unnatural L-α-amino acid fragments; X is a (C2-C4) unsaturated alkylene linking group; Da, Db and Dc are each =CH-: U is selected from the group consisting of -CH<sub>2</sub>- and -CH(OH)-; and Z is selected from the group consisting of -CH2-, -O-, -NH- and -S-.
- 44. The pharmaceutical composition of claim 43, wherein X is an unsaturated alkylene moiety selected from the group consisting of -C(CH<sub>3</sub>)=CH and -CH=C(CH<sub>3</sub>).
- The pharmaceutical composition of claim 33, wherein R<sup>1</sup> and R<sup>2</sup> are 45. each members independently selected from the group consisting of (C1-C8)alkyl, aryl and aryl(C1-C8)alkyl.
- The pharmaceutical composition of claim 43, wherein R<sup>1</sup> and R<sup>2</sup> are 46. each members independently selected from the group consisting of (C1-C8)alkvl. arvl and aryl(C1-C8)alkyl.
- 47. The pharmaceutical composition of claim 33, wherein R1 is an optionally substituted phenyl group.
- 1 48. The pharmaceutical composition of claim 33, wherein R1 is an optionally substituted phenyl group and R2 is an optionally substituted benzyl group. 2
  - The pharmaceutical composition of claim 43, wherein R1 is an 49. optionally substituted phenyl group.
  - 50. The pharmaceutical composition of claim 43, wherein R1 is an optionally substituted phenyl group and R2 is an optionally substituted benzyl group.
- The pharmaceutical composition of claim 33, wherein R1 is an 1 51. optionally substituted (C<sub>1</sub>-C<sub>8</sub>)alkyl or (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl group and R<sup>2</sup> is an optionally 2 3 substituted phenyl or benzyl group.

2 3

4

5

1

2 3

1

- The pharmaceutical composition of claim 33, wherein R<sup>1</sup> is a phenyl 52 group substituted with up to two members selected from the group consisting of -NHCONH2. -C(NH)NH2, -CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH<sub>2</sub>NHCO-CH=CH-(3-nitrophenyl), -CH<sub>3</sub>, -Cl, -Br, -I, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, -OH, -Ph, -OPh, -CON(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl).
- The pharmaceutical composition of claim 43, wherein R<sup>1</sup> is an 53. optionally substituted (C1-C8)alkyl or (C1-C8)heteroalkyl group and R2 is an optionally substituted phenyl or benzyl group.
- The pharmaceutical composition of claim 43, wherein R1 is a phenyl 54. group substituted with up to two members selected from the group consisting of -NHCONH<sub>2</sub>. -C(NH)NH2, -CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3-nitrophenyl), -CH3, -Cl, -Br, -I, -CO2H, -CO2CH3, -OCH3, -OH, -Ph, -OPh, -CON(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl).
- The pharmaceutical composition of claim 43, wherein Z is -O-; R<sup>1</sup> is a 55. member selected from the group consisting of an optionally substituted phenyl group or an optionally substituted heteroaryl; and R2 is a member selected from the group consisting of (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl(C1-C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl(C1-C<sub>8</sub>)alkyl and heteroaryl(C<sub>1</sub>-C<sub>8</sub>)heteroalkyl.
- The pharmaceutical composition of claim 36, wherein A<sup>1</sup> is an L-α-56. 1 amino acid fragment derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-2 3 proline.
- The pharmaceutical composition of claim 37, wherein A2 is an L-α-1 57. amino acid fragment derived from L-valine, L-leucine, L-methionine, L-lysine, L-isoluecine, 2 3 L-threonine and L-tert-butylglycine.
- The pharmaceutical composition of claim 43, wherein A<sup>1</sup> is an L-α-58. 1 amino acid fragment derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-2 proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from L-valine, L-leucine, L-3 methionine, L-lysine, L-isoluecine, L-threonine and L-tert-butylglycine. 4

6

7

8

9 10

11

12

13

1

2

3

4

1

2

3 1

2 3

The pharmaceutical composition of claim 58, wherein R<sup>1</sup> and R<sup>2</sup> are 59 each members independently selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl, substituted or unsubstituted aryl and substituted or unsubstituted arvl(C1-C8)alkvl.

- The pharmaceutical composition of claim 59, wherein A<sup>1</sup> is an L-α-60 amino acid fragment derived from L-alanine or L-proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from L-valine, L-leucine, L-isoluecine, or L-tert-butylglycine,
- 61. The pharmaceutical composition of claim 59, wherein A<sup>1</sup> is an L-αamino acid fragment derived from L-proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from L-tert-butylglycine.
- 62. The pharmaceutical composition of claim 33, said compound having the formula:

wherein

W1 is a member selected from the group consisting of -H, -OR15 and

-NR 15R 16:

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group consisting of hydrogen, halogen, -R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>;

wherein R15, R16, R17 and R18 are each members independently selected from the group consisting of hydrogen, arvl. (C1-C8)alkyl. (C1-C8)heteroalkyl, arvl(C1-C8)alkyl. arvl(C1-C8)heteroalkyl, alkylsulfonyl, arvlsulfonyl and arvlsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

1 63. The pharmaceutical composition of claim 33, said compound having 2 the formula:

5

6

7

8

3

wherein

-NR 15R 16:

 $R^2 \ is \ a \ member \ selected \ from \ the \ group \ consisting \ of \ substituted \ or \ unsubstituted \ (C_1\text{-}C_8)alky1;$ 

 $\boldsymbol{W}^{1}$  is a member selected from the group consisting of –H, –OR  $^{15}$  and

W<sup>2</sup> is a member selected from the group consisting of hydrogen, halogen,

-R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>; 
$$\text{wherein } R^{15}, R^{16}, R^{17} \text{ and } R^{18} \text{ are each members independently selected from }$$

the group consisting of hydrogen, aryl,  $(C_1-C_8)$ alkyl,  $(C_1-C_8)$ heteroalkyl, aryl $(C_1-C_8)$ alkyl, aryl $(C_1-C_8)$ alkyl, aryl $(C_1-C_8)$ alkyl, arylsulfonyl, arylsulfonyl and arylsulfinyl;

 $\label{eq:consisting} U \mbox{ and } Z \mbox{ are each members independently selected from the group consisting} \\ \mbox{ of -CH$_2$^-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R$^{13})-.} \\$ 

64. The pharmaceutical composition of claim 33, said compound having the formula:

$$V_2^1$$
  $V_2^1$   $V_3^2$   $V_4^3$   $V_4^4$   $V_5^4$   $V_5^4$   $V_5^4$   $V_8^4$   $V_8^4$   $V_8^4$ 

wherein

 $W^{1}$  is a member selected from the group consisting of -H,  $-OR^{15}$  and  $-NR^{15}R^{16}$ :

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group consisting of hydrogen, halogen, ¬R<sup>17</sup>, ¬CO<sub>2</sub>R<sup>17</sup>, ¬OR<sup>17</sup>, ¬NR<sup>17</sup>R<sup>18</sup> and ¬CONR<sup>17</sup>R<sup>18</sup>;

wherein  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  and  $R^{18}$  are each members independently selected from the group consisting of hydrogen, aryl,  $(C_1-C_8)$ alkyl,  $(C_1-C_8)$ heteroalkyl, aryl( $(C_1-C_8)$ heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl;

U and Z are each members independently selected from the group consisting of -CH<sub>2</sub>-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R<sup>13</sup>)-.

65. A method for modulating a STAT6-dependent condition in a host, comprising administering to said host a STAT6-modulating amount of a compound of the formula:

$$\overset{Y^1}{Y^2} \overset{U}{\underset{Z}{\longleftarrow}} \overset{D_c}{\underset{D_a}{\bigcap}} \overset{X}{\underset{O}{\bigcap}} \overset{A^2}{\underset{O}{\bigcap}} \overset{R^1}{\overset{N}{N}} R^2$$

wherein

 $R^1$  and  $R^2$  are each members independently selected from the group consisting of hydrogen,  $(C_1\text{-}C_8)$  alkyl,  $(C_1\text{-}C_8)$  heteroalkyl, aryl, heteroaryl, aryl( $C_1\text{-}C_8)$  alkyl, aryl( $C_1\text{-}C_8$ ) heteroalkyl, heteroaryl( $C_1\text{-}C_8$ ) heteroalkyl, with the proviso that at least one of  $R^1$  and  $R^2$  is selected from the group consisting of aryl, heteroaryl, aryl( $C_1\text{-}C_8$ ) alkyl, aryl( $C_1\text{-}C_8$ ) heteroalkyl, heteroaryl( $C_1\text{-}C_8$ ) alkyl and heteroaryl( $C_1\text{-}C_8$ ) heteroalkyl;

 $A^I \ \ is \ a \ member \ selected \ from \ the \ group \ consisting \ of \ L-\alpha-amino \ acid \ fragments, \ D-\alpha-amino \ acid \ fragments \ having \ the \ formula:$ 

15 wherein

 $R^3$  is selected from the group consisting of hydrogen and  $(C_1\text{-}C_4)$  alkyl;  $R^4$  and  $R^5$  are each members independently selected from the group consisting of hydrogen,  $(C_1\text{-}C_8)$ alkyl and  $(C_1\text{-}C_8)$ heteroalkyl, or can be individually combined with  $R^3$  to form a 5-, 6-, 7- or 8-membered ring containing from one to three heteroatoms;

 $A^2$  is a member selected from the group consisting of L- $\alpha$ -amino acid fragments, D- $\alpha$ -amino acid fragments and fragments having the formula:

44

45

46

47

48

49 50

51 52



24 wherein

23

25 R<sup>6</sup> is selected from the group consisting of hydrogen and (C<sub>1</sub>-C<sub>4</sub>)alkyl;
26 R<sup>7</sup> and R<sup>8</sup> are each members independently selected from the group
27 consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, or can be
28 combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to
29 three heteroatoms;

X is a member selected from the group consisting of a bond, a  $(C_1-C_4)$  saturated or unsaturated alkylene linking group and a  $(C_1-C_4)$  saturated or unsaturated heteroalkylene linking group;

 $D_{ab}\,D_{b}\,\text{and}\,D_{c}\,\text{are each independently selected from the group consisting of}$  =N- and =C(R)-

wherein

each R9 is independently selected from the group consisting of hydrogen,

halogen, cyano, nitro,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ heteroalkyl,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ thioalkoxy, - NR<sup>10</sup>R<sup>11</sup>, -C(O)OR<sup>10</sup>, -C(O)NR<sup>10</sup>R<sup>11</sup>, -O-C(O)OR<sup>10</sup>, -NR<sup>11</sup>-C(O)OR<sup>10</sup>, -NR<sup>10</sup>-SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, and -OC(O)NR<sup>10</sup>R<sup>11</sup>:

wherein

each  $R^{10}$  and  $R^{11}$  are each independently a member selected from the group consisting of hydrogen,  $(C_1-C_8)$ alkyl and  $(C_1-C_8)$ heteroalkyl, or when attached to the same nitrogen atom can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms; and

 $each\ R^{12}\ is\ independently\ a\ member\ selected\ from\ the\ group\ consisting\ of\ (C_1-C_8)alkyl,\ (C_1-C_8)heteroalkyl,\ aryl\ and\ heteroaryl;$ 

U and Z are each independently selected from the group consisting of a single bond,  $-CH_2$ -, -CH(OH)-, -C(O)-,  $-CH_2O$ -,  $-CH_2CH_2$ -,  $-CH_2C(O)$ -, -O-, -S-, -S- $-CH_2$ -, -N(C(O)- $-(C_1$ - $-C_2$ )alkyl)-,  $-N(R^{13})$ - and  $-N(R^{13})$ - $-CH_2$ -;

wherein

each  $\mathbb{R}^{13}$  is a member selected from the group consisting of hydrogen, ( $C_i$ - $C_s$ )alkyl, aryl and ( $C_i$ - $C_s$ )heteroalkyl;

2

3

75

- Y<sup>1</sup> and Y<sup>2</sup> are each independently selected from the group consisting of -53 CO2H and -CO2R14; and 54 R<sup>14</sup> is a member selected from the group consisting of (C<sub>1</sub>-C<sub>0</sub>)alkyl, and (C<sub>1</sub>-55 Co)heteroalkyl, or, alternatively, when Y1 and Y2 are each -CO<sub>2</sub>R14, each R14 and the oxygen 56 to which it is attached, join to form a 5-, 6-, 7- or 8-membered heterocyclic ring. 57 1 66. The method of claim 65, wherein D<sub>a</sub>, D<sub>b</sub> and D<sub>c</sub> are each =CH-. The method of claim 65, wherein X is a (C2-C4) unsaturated alkylene 1 67. 2 linking group. The method of claim 65, wherein A1 is selected from the group 1 68. consisting of L-\alpha-amino acid fragments. 2 1 2 1 2 3 The method of claim 65, wherein A2 is selected from the group 69 consisting of L-α-amino acid fragments. The method of claim 65, wherein A<sup>1</sup> and A<sup>2</sup> are each independently 70. selected from the group consisting of L-α-amino acid fragments. The method of claim 65, wherein A<sup>1</sup> and A<sup>2</sup> are each independently 71. selected from the group consisting of L-\alpha-amino acid fragments; X is a (C2-C4) unsaturated alkylene linking group; and Do, Db and Dc are each =CH-. 1 72 The method of claim 65, wherein U is selected from the group 2 consisting of -CH2- and -CH(OH)-. 1 73. The method of claim 65, wherein Z is selected from the group 2 consisting of -CH2-, -O-, -NH- and -S-. 1 74. The method of claim 65, wherein U is selected from the group 2 consisting of -CH<sub>2</sub>- and -CH(OH)-; and Z is selected from the group consisting of -CH<sub>2</sub>-, -O-3 , -NH- and -S-. The method of claim 65, wherein A1 and A2 are each independently
  - 67

selected from the group consisting of a natural or unnatural L-\alpha-amino acid fragments; X is a

(C<sub>2</sub>-C<sub>4</sub>) unsaturated alkylene linking group; D<sub>2</sub>, D<sub>3</sub> and D<sub>5</sub> are each =CH-; U is selected from

- 4 the group consisting of -CH<sub>2</sub>- and -CH(OH)-; and Z is selected from the group consisting of 5 -CH<sub>2</sub>-, -O-, -NH- and -S-.
- 1 76. The method of claim 75, wherein X is an unsaturated alkylene moiety selected from the group consisting of -C(CH<sub>3</sub>)=CH and -CH=C(CH<sub>3</sub>).
- 77. The method of claim 65, wherein R<sup>1</sup> and R<sup>2</sup> are each members
   independently selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl and aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl.
- 78. The method of claim 75, wherein R<sup>1</sup> and R<sup>2</sup> are each members
   independently selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl and aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl.
- - $\label{eq:R1} \textbf{80}. \qquad \text{The method of claim 65, wherein $R^1$ is an optionally substituted phenyl group and $R^2$ is an optionally substituted benzyl group.}$
  - $\textbf{81.} \qquad \text{The method of claim 75, wherein } R^1 \text{ is an optionally substituted phenyl} \\ \text{group.}$
  - 82. The method of claim 75, wherein  $R^1$  is an optionally substituted phenyl group and  $R^2$  is an optionally substituted benzyl group.
- 1 83. The method of claim 65, wherein  $R^1$  is an optionally substituted ( $C_1$ 2  $C_8$ )alkyl or ( $C_1$ - $C_8$ )heteroalkyl group and  $R^2$  is an optionally substituted phenyl or benzyl
  3 group.
- 1 84. The method of claim 65, wherein R<sup>1</sup> is a phenyl group substituted with 2 up to two members selected from the group consisting of -NHCONH<sub>2</sub>, -C(NH)NH<sub>2</sub>, -
- 3 CONH<sub>2</sub>, -CH<sub>2</sub>NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>NHCO-CH=CH-(3-
- 4 nitrophenyl), -CH<sub>3</sub>, -Cl. -Br. -I. -CO<sub>2</sub>H. -CO<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, -OH, -Ph. -OPh. -CO<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>, -
- 5  $C(CH_3)_3$ , -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl).
- 1 85. The method of claim 75, wherein R<sup>1</sup> is an optionally substituted (C<sub>1</sub>-
- $2 \quad \ C_8) alkyl \ or \ (C_1 C_8) heteroalkyl \ group \ and \ R^2$  is an optionally substituted phenyl or benzyl
- 3 group.

1

- The method of claim 75, wherein R<sup>1</sup> is a phenyl group substituted with 1 86 up to two members selected from the group consisting of -NHCONH<sub>2</sub>, -C(NH)NH<sub>2</sub>, -2 CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3-3 nitrophenyl), -CH<sub>3</sub>, -Cl, -Br, -I, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, -OH, -Ph, -OPh, -CON(CH<sub>3</sub>)<sub>2</sub>, -4 5 C(CH<sub>2</sub>)<sub>2</sub>. -CH<sub>2</sub>NHAc, -CN and -CH<sub>2</sub>NHCO-CH=CH-(4-pyridyl).
- The method of claim 75, wherein Z is -O-; R<sup>1</sup> is a member selected 1 87. from the group consisting of an optionally substituted phenyl group or an optionally 2 substituted heteroaryl; and R2 is a member selected from the group consisting of (C1-C8)alkyl. 3 (C1-C8)heteroalkyl, arvl(C1-C8)alkyl, arvl(C1-C8)heteroalkyl, heteroarvl(C1-C8)alkyl and 4 5 heteroarvl(C1-C2)heteroalkvl.
  - The method of claim 68, wherein A<sup>1</sup> is an L-α-amino acid fragment 88. derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-proline.
  - 89. The method of claim 69, wherein A2 is an L-\alpha-amino acid fragment derived from L-valine, L-leucine, L-methionine, L-lysine, L-isoluecine, L-threonine and Ltert-butylglycine.
  - The method of claim 75, wherein A<sup>1</sup> is an L-α-amino acid fragment 90. derived from L-tyrosine, L-serine, L-methionine, L-alanine and L-proline; and A<sup>2</sup> is an L-αamino acid fragment derived from L-valine, L-leucine, L-methionine, L-lysine, L-isoluecine, L-threonine and L-tert-butylglycine.
  - The method of claim 90, wherein R1 and R2 are each members 91. independently selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl, substituted or unsubstituted aryl and substituted or unsubstituted aryl(C1-C8)alkyl.
- The method of claim 91, wherein A<sup>1</sup> is an L-α-amino acid fragment 1 92. derived from L-alanine or L-proline; and A<sup>2</sup> is an L-α-amino acid fragment derived from L-2 valine, L-leucine, L-isoluecine, or L-tert-butylglycine. 3
- The method of claim 91, wherein A1 is an L-α-amino acid fragment 1 93. derived from L-proline; and A2 is an L-α-amino acid fragment derived from L-tert-2 butylglycine. 3

2 3

4

5

6

7

2 3

4 5

6 7

8

9

The method of claim 65, wherein said compound has the formula: 94

$$V_{1}^{1}$$
  $V_{2}^{1}$   $V_{2}^{1}$   $V_{3}^{1}$   $V_{1}^{1}$   $V_{2}^{1}$   $V_{3}^{1}$   $V_{4}^{1}$   $V_{2}^{1}$   $V_{2}^{1}$   $V_{3}^{1}$   $V_{4}^{1}$   $V_{4$ 

wherein

W1 is a member selected from the group consisting of -H. -OR15 and

-NR15R16:

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group consisting of hydrogen, halogen, -R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>;

wherein R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are each members independently selected from the group consisting of hydrogen, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl(C1-C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-,

> 95. The method of claim 65, wherein said compound has the formula:

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \\ \end{array} \end{array} \begin{array}{c} \begin{array}{c} \\ \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c}$$

wherein

-NR 15R 16:

R<sup>2</sup> is a member selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl;

W1 is a member selected from the group consisting of -H, -OR15 and

W<sup>2</sup> is a member selected from the group consisting of hydrogen, halogen,  $-R^{17}$ ,  $-CO_2R^{17}$ ,  $-OR^{17}$ ,  $-NR^{17}R^{18}$  and  $-CONR^{17}R^{18}$ :

6

7

8

11

12 1

2

3

4

5

6

1

2

3

4

10

11

12 13

14

1

wherein R15, R16, R17 and R18 are each members independently selected from the group consisting of hydrogen, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, arvl(C1-C2)heteroalkyl, alkylsulfonyl, arvlsulfonyl and arvlsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

> The method of claim 65, wherein said compound has the formula: 96.

$$\begin{array}{c} V^1 \\ V^2 \\ V^2 \end{array}$$

wherein

W1 is a member selected from the group consisting of -H, -OR15 and

-NR 15R 16:

W<sup>2</sup> and W<sup>3</sup> are each members independently selected from the group consisting of hydrogen, halogen, -R<sup>17</sup>, -CO<sub>2</sub>R<sup>17</sup>, -OR<sup>17</sup>, -NR<sup>17</sup>R<sup>18</sup> and -CONR<sup>17</sup>R<sup>18</sup>;

wherein R15, R16, R17 and R18 are each members independently selected from the group consisting of hydrogen, aryl, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl, aryl(C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl(C1-C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl;

U and Z are each members independently selected from the group consisting of -CH2-, -CH(OH)-, -C(O)-, -O-, -S- and -N(R13)-.

- 97 A method in accordance with claim 65, wherein said STAT6dependent condition is selected from the group consisting of allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis, psoriasis, Churg-Strauss syndrome, delayedtype hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
- 98. A method for treating a condition in a host, comprising administering to said host an effective amount of a compound of claim 1, wherein said condition is selected from the group consisting of allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions.

alveolitis, psoriasis, Churg-Strauss syndrome, delayed-type hypersensitivity, urticaria, angiodema, eczema, scleroderma and systemic lupus erythematosus.

- 99. The method in accordance with claim 98, wherein said compound of claim 1 is administered in combination with a second therapeutic agent.
  - 100. The method in accordance with claim 99, wherein said second therapeutic agent is selected from the group consisting of loratidine, fluticasone propionate, beclametasone diproprionate, budesonide, salmeterol xinafoate, ipratropium bromide, fexofenadine hydrochloride, cetirizine dihydrochloride, triamcinolone acetonide, cromolyn, salbutamol, montelukast sodium, ketotifen hydrogen fumarate, formoterol, zafirlukast, momefasone furoate, azelastine hydrochloride, epinastine, seratrodast, captropril, rampril, zofenopril, colchicine, enalapril, lisinopril, trandolapril, gold sodium thiomalate, calcipotriene, cyclosporine, vinblastine and dapsone.
  - 101. The method in accordance with claim 99, wherein said compound of claim 1 and said second therapeutic agent are administered sequentially.
- 102. A method in accordance with claim 99, wherein said compound of claim 1 and said second therapeutic agent are administered concurrently.
- 103. A method in accordance with claim 99, wherein said compound of claim 1 and said second therapeutic agent are each administered at dosages of from 1/100 to 1/2 of their dosages when administered individually.
- 104. A method in accordance with claim 99, wherein said compound of claim 1 and said second therapeutic agent are each administered at dosages of from 1/10 to 1/4 of their dosages when administered individually.